Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024
04:05pm, Tuesday, 06'th Aug 2024
Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024 Core Illumina GAAP operating margin of 40.5% and non-GAAP operati
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
10:55am, Monday, 05'th Aug 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina launches new oncology menu for NovaSeq X Series customers
09:15am, Monday, 05'th Aug 2024
Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers SAN DIEGO , Aug. 5, 2
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
08:22am, Friday, 02'nd Aug 2024
Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.
Stay Ahead of the Game With Illumina (ILMN) Q2 Earnings: Wall Street's Insights on Key Metrics
10:20am, Thursday, 01'st Aug 2024
Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Tuesday, 30'th Jul 2024
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Illumina (ILMN) Could Beat Earnings Estimates Again
01:15pm, Monday, 22'nd Jul 2024
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet
11:00am, Monday, 22'nd Jul 2024
The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
3 Precision Medicine Stocks Tailoring Treatments
06:00am, Sunday, 21'st Jul 2024
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.
Illumina to Present Upcoming Strategy Update
04:05pm, Thursday, 18'th Jul 2024
SAN DIEGO , July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am P
Illumina (ILMN) Upgraded to Buy: Here's Why
01:05pm, Tuesday, 16'th Jul 2024
Illumina (ILMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
07:10am, Tuesday, 16'th Jul 2024
Life sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, LLC
What's Happening With Illumina Stock?
07:00am, Friday, 12'th Jul 2024
Illumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company's a
Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
04:05pm, Thursday, 11'th Jul 2024
SAN DIEGO , July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on
What's Going On With 10x Genomics Stock On Wednesday?
02:22pm, Wednesday, 10'th Jul 2024
Wednesday, Illumina Inc ILMN acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.
